The results showed that capmatinib could relieve colitis in mice, as manifested by reduced weight loss, decreased DAI scores, colon length, expression of tissue inflammatory factors, HE scores, ROS production, and immune cell infiltration, as well as an increased number of goblet cells and MUC2 expression (Figure 7J−Q and Figure S9A). The gene discussed is MUC2; the disease is colitis.